HYPERREACTIVE CELLULAR IMMUNITY IN MULTIPLE MYELOMA

To the Editor:

The demonstration of hyperreactive T cells in patients with multiple myeloma by Massaia et al1 is of particular interest for the understanding of the functional activity of the immune system in this disorder. Our data on neopterin serum concentrations in patients with multiple myeloma2 point to immunologic activation in this disease and, in addition, indicate prognostic importance of this activation marker.

Neopterin is synthesized in human monocytes and macrophages from guanosine triphosphate (GTP) after stimulation by interferon-γ,3 because the key enzyme of pteridine biosynthesis, GTP cyclohy-
drolase I, is regulated by interferon-γ. Neopterin has been identified as a useful in vivo indicator of the state of activation of the cellular immune system. In malignant diseases, increased neopterin levels in serum or increased neopterin urinary excretion have been shown to be an important indicator for an unfavorable course of the disease.

We have measured serum neopterin levels by immunoassay and interleukin-6 (IL-6) levels by bioassay in 44 patients with multiple myeloma. Both neopterin and IL-6 showed a significant positive correlation with tumor stage. By univariate survival analysis using the product-limit approach, both neopterin (P = .0001) and IL-6 (P = .025) were significant predictors of survival. However, when tumor stage was included in a multivariate proportional hazards model for survival, only neopterin and stage were jointly significant; whereas for IL-6 only a tendency towards additional predictive information not reaching statistical significance was observed. In several tested multivariate models, including a variety of potentially predictive markers such as stage, hemoglobin, renal function, and others, neopterin remained a significant predictor. The findings are compatible to data obtained in other cancers in which neopterin has been shown to be of important prognostic value independent of many other prognostic variables.

Our data indicate that the predictive information obtained by IL-6, which is an important paracrine growth factor in multiple myeloma, may in part be already contained in the tumor stage. In contrast, the predictive value of neopterin, which is regarded to be a marker for activation of early events of cellular immunity, remained significant in the multivariate models because neopterin data provide information on a different aspect of the disease.

In conclusion, our data on increased neopterin concentrations in patients with multiple myeloma are compatible with the presence of activated T cells as putative source of endogenous interferon-γ, and hence increased neopterin synthesis by macrophages, in such patients. Moreover, our findings of a significant correlation between endogenous neopterin serum levels and prognosis point to the clinical relevance of this activation state, which was demonstrated clearly by Massaia et al.

GILBERT REIBNEGGER
HELMUT WACHER
Institute of Medical Chemistry and Biochemistry
University of Innsbruck
Innsbruck, Austria

MICHAEL KRAINER
HEINZ LUDWIG
Department of Medicine II
University of Vienna
Vienna, Austria

MANFRED HEROLD
HEINZ HUBER
Department of Medicine
University of Innsbruck
Innsbruck, Austria

REFERENCES


RESPONSE

The increased serum neopterin concentrations reported by Reibnegger et al in multiple myeloma patients further confirm that cell-mediated immunity is under pressure in this disorder. It is possible that alerted myeloma T cells are a source of endogenous interferon-γ (IFN-γ) that stimulates neopterin production in monocytes and macrophages; resting bone marrow T cells may constitutively release low amounts of IFN-γ (2 to 3 U/mL) (personal observation). We have recently reported high serum neopterin concentrations in 63 multiple myeloma patients at diagnosis. Neopterin showed prognostic importance; median survival for patients with high values was 20 months, whereas it was 63.9 months for patients with low values (P < .003). Neopterin data are an additional evidence for the negative correlation between the activation state of cell-mediated immunity and the tumor progression in multiple myeloma. To explain this contradictory correlation, one can specu-
late that the immune system is unproductively engaged by the
tumor cells. Although negative, these relationships point out the
presence of specific interactions between T and tumor cells that
can be exploited to generate productive antitumor activity, ie, by
CD3 and/or interleukin-2 stimulations.

It is really important that neopterin remained a significant
predictor in a multivariate analysis. By exploring the status of
cell-mediated immunity (a feature extrinsic to the tumor cell clone),
neopterin provides prognostic informations that are different and
complementary to that provided by factors exploring intrinsic
features of the tumor cell clone (like the labeling index of bone
marrow myeloma cells, the tumor stage, etc). These data suggest

that neopterin is worthy to be included in the staging system of
multiple myeloma.

MASSIMO MASSAIA
ALBERTO BIANCHI
CARMELA ATTISANO
MARIO BOCCADORO
ALESSANDRO PILERI
Divisione Universitaria di Ematologia
Dipartimento di Medicina e Oncologia Sperimentale
Ospedale Molinette
Torino, Italy

REFERENCES

1. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H,
Huber H: Predictive value of interleukin-6 and neopterin in

2. Boccadoro M, Battaglio S, Omede P, Palumbo AP, Fusaro A,
Frieri R, Gallone G, Polloni R, Mosso R, De Filippi PG, Pileri A:
Increased serum neopterin concentrations as indicator of disease
severity and poor survival in multiple myeloma. Eur J Haematol
47:305, 1991

3. Dianzani U, Pileri A, Boccadoro M, Palumbo A, Pioppo P,
Bianchi A, Camponi A, Fossati G, Battaglio S, Massaia M:
Activated idiotype-reactive cells in suppressor/cytotoxic subpopu-
lations of monoclonal gammapathies: Correlation with diagnosis

Redoglia V, Pileri A: Multiple myeloma: Increased circulating
lymphocytes carrying plasma cell-associated antigens as an indica-
tor of poor survival. Blood 76:1375, 1990
Hyperreactive cellular immunity in multiple myeloma [letter; comment]

G Reibnegger, H Wachter, M Krainer, H Ludwig, M Herold and H Huber